Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation

American Journal of the Medical Sciences

Volumn 342, Issue 5, 2011, Pages 356-364

  Graham, David Y ^a   Jewell, Nicholas P ^b   Chan, Francis K L ^c  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Corticosteroids; Gastrointestinal bleeding; NSAID complications; Rofecoxib

Indexed keywords

CELECOXIB; CORTICOSTEROID; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ARTICLE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; HUMAN; INCIDENCE; MILD COGNITIVE IMPAIRMENT; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 80055051880     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182113658     Document Type: Article

References (42)

1. Angell M. The truth about the drug companies. How they deceive us and what to do about it. New York: Random house; 2004.
2. Moynihan R, Cassels A. Selling sickness. How the world's biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005.
3. Petersen M. Our daily med. How the pharmaceutical companies transformed themselves into slick marketing machines and hooked the nation on prescription drugs. New York: Sarah Crichton Books; 2008.
4. Ross JS, Hill KP, Egilman DS, et al. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008;299:1800-12. (Pubitemid 351549971)
5. Rostom A, Muir K, Dube C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007;5:818-28, 828.
6. Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications-review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004;19:1051-61. (Pubitemid 38703517)
7. Graham DY, Chan FK. NSAIDs, risks, and gastroprotective strategies: current status and future. Gastroenterology 2008;134:1240-6. (Pubitemid 351451996)
8. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282:1929-33.
9. Watson DJ, Yu Q, Bolognese JA, et al. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. Curr Med Res Opin 2004;20:1539-48. (Pubitemid 39457542)
10. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8, 2.
11. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002;123:1006-12.
12. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124:288-92. (Pubitemid 36169245)
13. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606. (Pubitemid 32171634)
14. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drugassociated gastrointestinal injury. Am J Med 1998;104:23S-29S; discussion 41S. (Pubitemid 28186991)
15. MacDonald TM. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology (Oxford) 2000;39(suppl 2):13-20. (Pubitemid 32186216)
16. Tielemans MM, Eikendal T, Jansen JB, et al. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf 2010;33:443-53.
17. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal antiinflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
18. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72; erratum in Lancet 1994 April 23;343(8904):1048. (Pubitemid 24098698)
19. Garcia Rodriguez LA, Barreales TL. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007;132:498-506. (Pubitemid 46274667)
20. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312:1563-6. (Pubitemid 26188573)
21. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000;43: 370-7. (Pubitemid 30395746)
22. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999;117:776-83. (Pubitemid 29468218)
23. Graham DY. Endoscopic ulcers are neither meaningful nor validated as a surrogate for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol 2009;7:1147-50.
24. Beejay U, Wolfe MM. Cyclooxygenase 2 selective inhibitors: panacea or flash in the pan? Gastroenterology 1999;117:1002-5. (Pubitemid 29468241)
25. Lanas A, Baron JA, Sandler RS, et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology 2007;132:490-7. (Pubitemid 46274654)
26. Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002;325:624-9.
27. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;331:1310-6.
28. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-8. (Pubitemid 44893570)
29. Castellsague J, Holick CN, Hoffman CC, et al. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. Pharmacotherapy 2009;29:1397-407.
30. Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004;27:411-20. (Pubitemid 38608459)
31. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9. (Pubitemid 30482713)
32. Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001;153:1089-93. (Pubitemid 32493258)
33. STATA Statistical software. College Station, Texas: StataCorp; 2009.
34. Cox DR. Regression models and life-tables (with discussion). J Royal Stat Soc B 1972;34:178-220.
35. Henry D, McGettigan P. Selective COX-2 inhibitors: a promise unfulfilled? Gastroenterology 2007;132:790-4. (Pubitemid 46274696)
36. Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 1996;91:2080-6. (Pubitemid 26338956)
37. Graham DY, Smith JL, Holmes GI, et al. Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa. Clin Pharmacol Ther 1985;38:65-70. (Pubitemid 15242202)
38. Saag K, van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Arch Fam Med 2000;9:1124-34. (Pubitemid 32014710)
39. Gonzalez EL, Patrignani P, Tacconelli S, et al. Variability of risk of upper gastrointestinal bleeding among nonsteroidal anti-inflammatory drugs. Arthritis Rheum 2010;62:1592-601.
40. Watanabe T, Sugimori S, Kameda N, et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008;6:1279-82.
41. Smecuol E, Pinto Sanchez MI, Suarez A, et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol 2009;7:524-9.
42. Shiotani A, Haruma K, Nishi R, et al. Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage. Scand J Gastroenterol 2010;45:292-8.